Cargando…

Personalized medicine and allergen immunotherapy: the beginning of a new era?

The concept of personalized medicine as a diagnostic and therapeutic approach tailored to the medical needs of each patient is currently revolutionizing all fields of medicine and in particular allergology. Allergen immunotherapy (AIT) meets the three main needs for precision medicine: identificatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Incorvaia, Cristoforo, Ridolo, Erminia, Bagnasco, Diego, Scurati, Silvia, Canonica, Giorgio Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262025/
https://www.ncbi.nlm.nih.gov/pubmed/34233706
http://dx.doi.org/10.1186/s12948-021-00150-z
_version_ 1783719115113889792
author Incorvaia, Cristoforo
Ridolo, Erminia
Bagnasco, Diego
Scurati, Silvia
Canonica, Giorgio Walter
author_facet Incorvaia, Cristoforo
Ridolo, Erminia
Bagnasco, Diego
Scurati, Silvia
Canonica, Giorgio Walter
author_sort Incorvaia, Cristoforo
collection PubMed
description The concept of personalized medicine as a diagnostic and therapeutic approach tailored to the medical needs of each patient is currently revolutionizing all fields of medicine and in particular allergology. Allergen immunotherapy (AIT) meets the three main needs for precision medicine: identification of molecular mechanism of disease, diagnostic tools for the mechanism and treatment blocking the mechanism itself. AIT adapts to the spectrum of specific IgE of each individual subject, changing the course and natural history of the disease, so is a clear model of precision and personalized medicine. This first step before the prescription of AIT is to define the sensitization profile of the patient; after that, the healthcare professional has numerous levers for adapting the treatment to the physio-pathological mechanisms involved. AIT allows to adapt treatments to the profile of the patients, but also to the its preferences, to ensure optimal treatment efficacy, resulting in an agile and personalized approach, with the aim to ensure adherence to the treatment, which is usually quite low. AIT also broadens the field of possibilities for healthcare professionals and patients, by allowing to choose the galenic formulation according to patient preferences and on the basis of their clinical history, adapting the product composition to the patient’s sensitization profiles and the underlying biological mechanisms identified at the diagnostic stage, while guaranteeing quality of the prescribed product as the production of allergens and allergoids is today more regulated than in the past years. In the management of AIT, it is also possible to involve patients in decisions throughout their care pathway thanks to multiple services, offering personalized follow-up and support, to ensure the highest treatment efficacy levels, and recalling medication intake, medical appointments and prescription renewals.
format Online
Article
Text
id pubmed-8262025
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82620252021-07-08 Personalized medicine and allergen immunotherapy: the beginning of a new era? Incorvaia, Cristoforo Ridolo, Erminia Bagnasco, Diego Scurati, Silvia Canonica, Giorgio Walter Clin Mol Allergy Commentary The concept of personalized medicine as a diagnostic and therapeutic approach tailored to the medical needs of each patient is currently revolutionizing all fields of medicine and in particular allergology. Allergen immunotherapy (AIT) meets the three main needs for precision medicine: identification of molecular mechanism of disease, diagnostic tools for the mechanism and treatment blocking the mechanism itself. AIT adapts to the spectrum of specific IgE of each individual subject, changing the course and natural history of the disease, so is a clear model of precision and personalized medicine. This first step before the prescription of AIT is to define the sensitization profile of the patient; after that, the healthcare professional has numerous levers for adapting the treatment to the physio-pathological mechanisms involved. AIT allows to adapt treatments to the profile of the patients, but also to the its preferences, to ensure optimal treatment efficacy, resulting in an agile and personalized approach, with the aim to ensure adherence to the treatment, which is usually quite low. AIT also broadens the field of possibilities for healthcare professionals and patients, by allowing to choose the galenic formulation according to patient preferences and on the basis of their clinical history, adapting the product composition to the patient’s sensitization profiles and the underlying biological mechanisms identified at the diagnostic stage, while guaranteeing quality of the prescribed product as the production of allergens and allergoids is today more regulated than in the past years. In the management of AIT, it is also possible to involve patients in decisions throughout their care pathway thanks to multiple services, offering personalized follow-up and support, to ensure the highest treatment efficacy levels, and recalling medication intake, medical appointments and prescription renewals. BioMed Central 2021-07-07 /pmc/articles/PMC8262025/ /pubmed/34233706 http://dx.doi.org/10.1186/s12948-021-00150-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Incorvaia, Cristoforo
Ridolo, Erminia
Bagnasco, Diego
Scurati, Silvia
Canonica, Giorgio Walter
Personalized medicine and allergen immunotherapy: the beginning of a new era?
title Personalized medicine and allergen immunotherapy: the beginning of a new era?
title_full Personalized medicine and allergen immunotherapy: the beginning of a new era?
title_fullStr Personalized medicine and allergen immunotherapy: the beginning of a new era?
title_full_unstemmed Personalized medicine and allergen immunotherapy: the beginning of a new era?
title_short Personalized medicine and allergen immunotherapy: the beginning of a new era?
title_sort personalized medicine and allergen immunotherapy: the beginning of a new era?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262025/
https://www.ncbi.nlm.nih.gov/pubmed/34233706
http://dx.doi.org/10.1186/s12948-021-00150-z
work_keys_str_mv AT incorvaiacristoforo personalizedmedicineandallergenimmunotherapythebeginningofanewera
AT ridoloerminia personalizedmedicineandallergenimmunotherapythebeginningofanewera
AT bagnascodiego personalizedmedicineandallergenimmunotherapythebeginningofanewera
AT scuratisilvia personalizedmedicineandallergenimmunotherapythebeginningofanewera
AT canonicagiorgiowalter personalizedmedicineandallergenimmunotherapythebeginningofanewera